| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Novartis Institute for Biomedical Research, LSB 3517, Summit, New Jersey 07901
The incretin glucagon-like
peptide-1 (GLP-1)-(7---36) amide is an important factor in prandial
glucose homeostasis. Findings that GLP-1 is rapidly inactivated led to
the hypothesis that the target of GLP-1 is close to the site of
release. To investigate whether the target tissue is located in the
hepatoportal system, we administered GLP-1 with glucose into the portal
vein of rats and compared this with peripheral GLP-1 administration
(jugular vein) and studied the effects of blockers of the nervous
system. Portal GLP-1 augmented the insulin response to a portal glucose bolus by 81% (P < 0.01) and markedly improved the
glucose disposal rate (P < 0.05). Peripheral
administration of GLP-1 produced a similar augmentation of the insulin
response (88%) and of the glucose disposal rate. However, only the
effect of portal GLP-1 on insulin secretion was blocked by the
ganglionic blocker chlorisondamine. The data suggest that prandial
-cell stimulation by GLP-1 is evoked via a neural reflex triggered
in the hepatoportal system. Because absorbed nutrients and GLP-1 first
appear in the portal system, this mechanism may constitute a major
pathway of GLP-1 action during meals.
glucagon-like peptide-1; incretin; autonomic nervous system
This article has been cited by other articles:
|
|
 |
|
  D. Tornehave, P. Kristensen, J. Romer, L. B. Knudsen, and R. S. Heller Expression of the GLP-1 Receptor in Mouse, Rat, and Human Pancreas J. Histochem. Cytochem., September 1, 2008; 56(9): 841 - 851. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Burcelin, P. D. Cani, and C. Knauf Glucagon-Like Peptide-1 and Energy Homeostasis J. Nutr., November 1, 2007; 137(11): 2534S - 2538S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Holst The Physiology of Glucagon-like Peptide 1 Physiol Rev, October 1, 2007; 87(4): 1409 - 1439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. S. Johnson, D. S. Edgerton, T. Rodewald, M. Scott, B. Farmer, D. Neal, and A. D. Cherrington Intraportal GLP-1 infusion increases nonhepatic glucose utilization without changing pancreatic hormone levels Am J Physiol Endocrinol Metab, October 1, 2007; 293(4): E1085 - E1091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fukaya, A. Mizuno, H. Arai, K. Muto, T. Uebanso, K. Matsuo, H. Yamamoto, Y. Taketani, T. Doi, and E. Takeda Mechanism of rapid-phase insulin response to elevation of portal glucose concentration Am J Physiol Endocrinol Metab, August 1, 2007; 293(2): E515 - E522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Ionut, I. F. Liberty, K. Hucking, M. Lottati, D. Stefanovski, D. Zheng, and R. N. Bergman Exogenously imposed postprandial-like rises in systemic glucose and GLP-1 do not produce an incretin effect, suggesting an indirect mechanism of GLP-1 action Am J Physiol Endocrinol Metab, October 1, 2006; 291(4): E779 - E785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Cani, C. Knauf, M. A. Iglesias, D. J. Drucker, N. M. Delzenne, and R. Burcelin Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like Peptide 1 receptor. Diabetes, May 1, 2006; 55(5): 1484 - 1490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Dardevet, M. C. Moore, C. A. DiCostanzo, B. Farmer, D. W. Neal, W. Snead, M. Lautz, and A. D. Cherrington Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors Am J Physiol Gastrointest Liver Physiol, November 1, 2005; 289(5): G806 - G814. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. K. Chelikani, A. C. Haver, and R. D. Reidelberger Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2005; 288(6): R1695 - R1706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Holst and C. Orskov The Incretin Approach for Diabetes Treatment: Modulation of Islet Hormone Release by GLP-1 Agonism Diabetes, December 1, 2004; 53(suppl_3): S197 - S204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Dardevet, M. C. Moore, D. Neal, C. A. DiCostanzo, W. Snead, and A. D. Cherrington Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region Am J Physiol Endocrinol Metab, July 1, 2004; 287(1): E75 - E81. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. D'Alessio and T. P. Vahl Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E882 - E890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Meier, M. A. Nauck, D. Kranz, J. J. Holst, C. F. Deacon, D. Gaeckler, W. E. Schmidt, and B. Gallwitz Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects Diabetes, March 1, 2004; 53(3): 654 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Cupples Endo-neuro-endocrine incretin pathways Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2004; 286(2): R250 - R250. [Full Text] [PDF]
|
|
|
|
|
|
B. Ahren Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2004; 286(2): R269 - R272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Prigeon, S. Quddusi, B. Paty, and D. A. D'Alessio Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect Am J Physiol Endocrinol Metab, October 1, 2003; 285(4): E701 - E707. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nishizawa, M. C. Moore, M. Shiota, S. M. Gustavson, W. L. Snead, D. W. Neal, and A. D. Cherrington Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs Am J Physiol Endocrinol Metab, May 1, 2003; 284(5): E1027 - E1036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Burcelin, A. Da Costa, D. Drucker, and B. Thorens Glucose Competence of the Hepatoportal Vein Sensor Requires the Presence of an Activated Glucagon-Like Peptide-1 Receptor Diabetes, August 1, 2001; 50(8): 1720 - 1728. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
